Developing Story: The Camizestrant Vote — When Your Blood Test Knows Before Your Scan Does

The ODAC Vote on Camizestrant & SERENA-6: A Patient Advocate Panel Weighs InWhen the FDA's Oncologic Drugs Advisory Committee voted 6-3 against recommending approval of camizestrant in the SERENA-6 trial setting, the MBC community had questions and opinions. Host Victoria gathered six of the most informed patient advocates in the metastatic breast cancer space for an unfiltered, expert conversation about what the vote really means.In this episode:What SERENA-6 was actually testing and why the trial design drew criticismWhy the ODAC vote was about when to switch therapy, not whether camizestrant is a good drugThe debate over progression-free survival vs. overall survival as endpointsMolecular progression vs. radiologic progression and whether we're ready to act on ctDNA aloneThe "burn through treatments" concern: what early switching means for long-term optionsInsurance coverage gaps for liquid biopsy testing and the two-tier care systemWhy patient advocates need a seat at the table before trials are designed and not afterWhat's next for camizestrant and the broader SERENA programFeaturing: Janice Cowden, Jill Tirabassi, Ellen Landsberger, Abigail Johnston, Kelly Shanahan, and Lynda WeatherbyThe ODAC vote isn't the end of the road for camizestrant , but it raises important questions about how we define progression, design trials, and include patient voices in the process. This conversation is a must-listen for anyone navigating treatment decisions in hormone receptor-positive MBC.Thanks for listening. If you enjoyed the episode, subscribe and leave a review — it really helps. Follow us on social media @livefromstage4 and visit our website at www.livefromstage4.org for show notes and links. Your support helps us continue to share important stories and advocate for those living with metastatic breast cancer.Until next time, take care and keep pushing for progress.